Effective July 1, 2014, Harvard Pilgrim is establishing a new medical policy for allergy immunotherapy. Under this policy, Harvard Pilgrim will not cover sublingual immunotherapy but will cover subcutaneous immunotherapy for the following conditions:
- Allergic rhinitis
- Allergic asthma
- Stinging insect allergy
- Allergic conjunctivitis
- Atopic dermatitis
Immunotherapy involves gradually introducing patients to small doses of the allergens to which they are sensitive, with the dose increasing gradually over time, to build tolerance to the allergen and improve symptoms. With sublingual immunotherapy, the allergen is given as drops under the tongue; subcutaneous immunotherapy is delivered via injections.
For more information, including a list of covered ICD-9 and CPT codes, please refer to the Allergy Immunotherapy Medical Policy.